A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

by Wu-tong Ju, Rong-hui Xia, Dong-wang Zhu, Sheng-jin Dou, Guo-pei Zhu, Min-jun Dong, Li-zhen Wang, Qi Sun, Tong-chao Zhao, Zhi-hang Zhou, Si-yuan Liang, Ying-ying Huang, Yong Tang, Si-cheng Wu, Jing Xia, Shi-qing Chen, Yue-zong Bai, Jiang Li, Qi Zhu, Lai-ping Zhong
Published 2022-09-01